Heron Therapeutics, Inc.
HRTX
$0.40
-$0.05-10.74%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -10.78% | -0.47% | 16.47% | 3.26% | 12.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.78% | -0.47% | 16.47% | 3.26% | 12.21% |
| Cost of Revenue | 21.30% | 10.88% | 10.49% | -14.44% | -17.74% |
| Gross Profit | -23.00% | -6.03% | 20.87% | 15.83% | 30.29% |
| SG&A Expenses | 5.76% | 10.70% | 15.32% | -5.35% | -5.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.43% | 10.77% | 13.52% | -8.55% | -9.42% |
| Operating Income | -251.08% | -99.09% | 8.19% | 74.60% | 165.74% |
| Income Before Tax | -407.82% | -180.64% | -260.87% | 74.22% | 183.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -407.82% | -180.64% | -260.87% | 74.22% | 183.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -407.82% | -180.64% | -260.87% | 74.22% | 183.39% |
| EBIT | -251.08% | -99.09% | 8.19% | 74.60% | 165.74% |
| EBITDA | -214.33% | -87.90% | 10.29% | 82.32% | 190.17% |
| EPS Basic | -348.84% | -165.69% | -223.97% | 74.42% | 182.30% |
| Normalized Basic EPS | -349.53% | -137.00% | -14.14% | 74.41% | 181.68% |
| EPS Diluted | -528.00% | -165.69% | -223.97% | 67.00% | 147.85% |
| Normalized Diluted EPS | -417.86% | -137.00% | -14.14% | 74.41% | 164.12% |
| Average Basic Shares Outstanding | 23.56% | 22.77% | 11.46% | 1.13% | 1.52% |
| Average Diluted Shares Outstanding | -3.69% | 22.77% | 11.46% | 1.13% | 30.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |